AMD announced its first life sciences collaboration with AI-based drug developer Absci, providing its hardware and software for Absci’s AI drug discovery. Despite AMD also investing $20m in Absci, its shares fell 4% after HSBC analyst Frank Lee downgraded the firm from “Buy” to “Reduce” and cut its price target by 18%, suggesting AMD will continue trailing market leader Nvidia. This is AMD’s first life-sciences partnership.
Microsoft sues service for creating illicit content with its AI platform
Microsoft and other companies ban the use of their AI systems to create inappropriate or harmful content. Despite precautions, this restriction has been bypassed through
